These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 37891632)

  • 1. "That's why we're speaking up today": exploring barriers to overdose fatality prevention in Indianapolis' Black community with semi-structured interviews.
    Seo DC; Satterfield N; Alba-Lopez L; Lee SH; Crabtree C; Cochran N
    Harm Reduct J; 2023 Oct; 20(1):159. PubMed ID: 37891632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'It's the same thing as giving them CPR training': rural first responders' perspectives on naloxone.
    Filteau MR; Green B; Kim F; McBride KA
    Harm Reduct J; 2022 Oct; 19(1):111. PubMed ID: 36192736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Community-based naloxone coverage equity for the prevention of opioid overdose fatalities in racial/ethnic minority communities in Massachusetts and Rhode Island.
    Nolen S; Zang X; Chatterjee A; Behrends CN; Green TC; Kumar A; Linas BP; Morgan JR; Murphy SM; Walley AY; Yan S; Schackman BR; Marshall BDL
    Addiction; 2022 May; 117(5):1372-1381. PubMed ID: 34825427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Barriers and facilitators of naloxone and safe injection facility interventions to reduce opioid drug-related deaths: A qualitative analysis.
    Miller NM; Campbell C; Shorter GW
    Int J Drug Policy; 2023 Jul; 117():104049. PubMed ID: 37247475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A qualitative examination of naloxone access in three states: Connecticut, Kentucky, and Wisconsin.
    Spector AL; Galletly CL; Christenson EA; Montaque HDG; Dickson-Gomez J
    BMC Public Health; 2022 Jul; 22(1):1387. PubMed ID: 35854278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naloxone administration by law enforcement officers in New York State (2015-2020).
    Pourtaher E; Payne ER; Fera N; Rowe K; Leung SJ; Stancliff S; Hammer M; Vinehout J; Dailey MW
    Harm Reduct J; 2022 Sep; 19(1):102. PubMed ID: 36123614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harm Reduction in the Field: First Responders' Perceptions of Opioid Overdose Interventions.
    Elswick Fockele C; Frohe T; McBride O; Perlmutter DL; Goh B; Williams G; Wettemann C; Holland N; Finegood B; Oliphant-Wells T; Williams EC; van Draanen J
    West J Emerg Med; 2024 Jul; 25(4):490-499. PubMed ID: 39028235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A qualitative study of repeat naloxone administrations during opioid overdose intervention by people who use opioids in New York City.
    Parkin S; Neale J; Brown C; Jones JD; Brandt L; Castillo F; Campbell ANC; Strang J; Comer SD
    Int J Drug Policy; 2021 Jan; 87():102968. PubMed ID: 33096365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An exploratory study of a hands-on naloxone training for rural clinicians and staff.
    Cody SL; Hines CB; Glenn CJ; Sharp-Marbury R; Newman S
    J Nurs Scholarsh; 2023 May; 55(3):599-604. PubMed ID: 36411494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study.
    Slocum S; Ozga JE; Joyce R; Walley AY; Pollini RA
    BMC Public Health; 2022 Apr; 22(1):735. PubMed ID: 35418048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient, family members and community pharmacists' views of a proposed overdose prevention intervention delivered in community pharmacies for patients prescribed high-strength opioids for chronic non-cancer pain: An explorative intervention development study.
    Mercer F; Parkes T; Foster R; Steven D; McAuley A; Baldacchino A; Steele W; Schofield J; Matheson C
    Drug Alcohol Rev; 2023 Mar; 42(3):517-526. PubMed ID: 36165733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naloxone analogy and opioid overdose terminology preferences among rural caregivers: Differences by race.
    Hosea K; Mashburn P; Kennelty K; Westrick SC; Look K; Evon D; Carpenter DM
    J Am Pharm Assoc (2003); 2023; 63(5):1521-1529.e3. PubMed ID: 37149142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of the distribution of take-home naloxone in low- and middle-income countries and barriers to the implementation of take-home naloxone programs.
    Sajwani HS; Williams AV
    Harm Reduct J; 2022 Oct; 19(1):117. PubMed ID: 36266701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Legacies of the war on drugs: Next of kin of persons who died of opioid overdose and harm reduction interventions in Philadelphia.
    Uzwiak BA; Hudgins A; Pizzicato LN
    Int J Drug Policy; 2021 Nov; 97():103351. PubMed ID: 34252788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Considerations for the design of overdose education and naloxone distribution interventions: results of a multi-stakeholder workshop.
    Sellen K; Markowitz B; Parsons JA; Leece P; Handford C; Goso N; Hopkins S; Klaiman M; Shahin R; Milos G; Wright A; Charles M; Morrison L; Strike C; Orkin A;
    BMC Public Health; 2023 May; 23(1):888. PubMed ID: 37189052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overdose responses among rural people who use drugs: A multi-regional qualitative study.
    Baker R; Fredericksen RJ; Rudolph AE; Stopka TJ; Walters SM; Fadanelli M; Bolinski RS; Sibley AL; Stack E; Crane HM; Korthuis PT; Seal DW
    Harm Reduct J; 2024 May; 21(1):107. PubMed ID: 38822387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personal experience and awareness of opioid overdose occurrence among peers and willingness to administer naloxone in South Africa: findings from a three-city pilot survey of homeless people who use drugs.
    Wilson M; Brumwell A; Stowe MJ; Shelly S; Scheibe A
    Harm Reduct J; 2022 Feb; 19(1):17. PubMed ID: 35148779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
    Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
    Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid Overdoses and Take-Home Naloxone Interventions: Ethnographic Evidence for Individual-Level Barriers to Treatment of Opioid Use Disorders in Rural Appalachia.
    Garcia V; McCann L; Lauber E; Vaccaro C; Swauger M; Heckert DA
    Subst Use Misuse; 2024; 59(9):1313-1322. PubMed ID: 38635977
    [No Abstract]   [Full Text] [Related]  

  • 20. Factors associated with gaps in naloxone knowledge: evidence from a 2022 great plains survey.
    Cooper-Ohm S; Habecker P; Humeniuk R; Bevins RA
    Harm Reduct J; 2024 Feb; 21(1):37. PubMed ID: 38336722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.